GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Retained Earnings

Hansoh Pharmaceutical Group Co (HKSE:03692) Retained Earnings : HK$11,492 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Hansoh Pharmaceutical Group Co's retained earnings for the quarter that ended in Dec. 2023 was HK$11,492 Mil.

Hansoh Pharmaceutical Group Co's quarterly retained earnings increased from Dec. 2022 (HK$8,811 Mil) to Jun. 2023 (HK$9,742 Mil) and increased from Jun. 2023 (HK$9,742 Mil) to Dec. 2023 (HK$11,492 Mil).

Hansoh Pharmaceutical Group Co's annual retained earnings increased from Dec. 2021 (HK$0 Mil) to Dec. 2022 (HK$8,811 Mil) and increased from Dec. 2022 (HK$8,811 Mil) to Dec. 2023 (HK$11,492 Mil).


Hansoh Pharmaceutical Group Co Retained Earnings Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Retained Earnings Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial - - - 8,811.00 11,491.64

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 8,811.00 9,742.14 11,491.64

Hansoh Pharmaceutical Group Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Hansoh Pharmaceutical Group Co  (HKSE:03692) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines